We examined the impact of the preprocedural triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio on risk of in-stent restenosis (ISR). Patients with typical anginal symptoms and/or positive treadmill or myocardial perfusion scintigraphy test results who underwent successful coronary stent implantation due to stable angina were examined; 1341 patients were enrolled. The hospital files of the patients were used to gather data. Cox regression analysis showed that the TG/HDL-C ratio was independently associated with the presence of ISR (P < .001). Moreover, diabetes mellitus (P = .007), smaller stent diameter (P = .046), and smoking status (P = .001) were also independently associated with the presence of ISR. Using a cutoff of 3.8, the TG/HDL-C ratio predicted the presence of ISR with a sensitivity of 71% and a specificity of 68%. Also, the highest quartile of TG/HDL-C ratio had the highest rate of ISR (P < .001). Measuring preprocedural TG/HDL-C ratio, in fasting or nonfasting samples, could be beneficial for the risk assessment of ISR. However, further large-scale prospective studies are required to establish the exact role of this simple, easily calculated, and reproducible parameter in the pathogenesis of ISR.
MisraPReddyPCShuklaDCalditoGCYerraLAwTY. In-stent stenosis: potential role of increased oxidative stress and glutathione-linked detoxification mechanisms. Angiology. 2008;59(4):469–474.
2.
KornowskiRHongMKTioFOBramwellOWuHLeonMB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1):224–230.
3.
WeltFGRogersC. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769–1776.
4.
JuniRPDuckersHJVanhouttePMVirmaniRMoensAL. Oxidative stress and pathological changes after coronary artery interventions. J Am Coll Cardiol. 2013;61(14):1471–1481.
5.
HokansonJEAustinMA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213–219.
6.
SarwarNDaneshJEiriksdottirG. Triglycerides and the risk of coronary heart disease 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation. 2007;115(4):450–458.
7.
GrundySM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81(4):18–25.
8.
HafianeAGenestJ. High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 2015;3:175–188.
9.
LewingtonSWhitlockGClarkeR; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–1839.
10.
MillánJPintóXMuñozA. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–765.
11.
OnatACanGKayaHHergencG. “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010;4(2):89–98.
12.
SalazarMRCarbajalHAEspecheWG. Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular disease in hypertensive subjects. J Am Soc Hypertens. 2014;8(10):724–731.
13.
RizosEMikhailidisDP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol. 2002;82(3):199–207.
14.
VegaGLBarlowCEGrundySMLeonardDDeFinaLF. Triglyceride-to-high-density lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. J Investig Med. 2014;62(2):345–349.
15.
LevineGNBatesERBlankenshipJC; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):44–122.
16.
SmithSCDoveJTJacobsAK; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) 333: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 2001;37(8):2239–2342.
17.
MehranRDangasGAbizaidAS. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–1878.
18.
InoueTCroceKMorookaTSakumaMNodeKSimonDI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057–1066.
19.
NiccoliGMontoneRAFerranteGCreaF. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56(22):1783–1793.
20.
FerranteGNiccoliGBiasucciLM. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008;9(3):156–165.
21.
RahelBMVisserenFLSuttorpMJ. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60(1):136–140.
22.
TurkerSGuneriSAkdenizB. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol. 2006;97(2):198–202.
23.
TurakOCanpolatUÖzcanF. Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Am J Cardiol. 2014;113(2):197–202.
24.
Murguıa-RomeroMJimenez-FloresJRSigrist-FloresSC. Plasma triglyceride/HDL-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J Lipid Res. 2013;54(10):2795–2799.
25.
McLaughlinTReavenGAbbasiF. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?Am J Cardiol. 2005;96(3):399–404.
26.
SalazarMRCarbajalHAEspecheWG. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol. 2012;109(12):1749–1753.
27.
SalazarMRCarbajalHAEspecheWG. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab Vasc Dis Res. 2013;10(4):346–352.
28.
RazaniBChakravarthyMVSemenkovichCF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am. 2008;37(3):603–621.
29.
WassinkAMvan der GraafYOlijhoekJKVisserenFL; SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2008;29(2):213–223.
30.
KitogaMPasquetAPreumontV. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. Diabetes Metab. 2008;34(1):62–67.
31.
AbizaidAKornowskiRMintzGS. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32(3):584–589.
32.
St-PierreACCantinBDagenaisGR. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25(3):553–559.
33.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
34.
VarboABennMTybjærg-HansenAJørgensenABFrikke-SchmidtRNordestgaardBG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436.
35.
HoogeveenRCGaubatzJWSunW. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069–1077.
36.
LangstedAFreibergJJTybjaerg-HansenASchnohrPJensenGBNordestgaardBG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011;270(1):65–75.
37.
KolovouGDMikhailidisDPKovarJ. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9(3):258–270.
38.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–324.
39.
MurphyAJWoollardKJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37(7):710–718.
40.
MurphyAJChin-DustingJPSviridovDWoollardKJ. The anti-inflammatory effects of high density lipoproteins. Curr Med Chem. 2009;16(6):667–675.
41.
HesslerJRRobertsonALJrChisolmGMIII. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979;32(3):213–229.
42.
LiXPZhaoSPZhangXYLiuLGaoMZhouQC. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol. 2000;73(3):231–236.
43.
SeoSMChooEHKohYS; Catholic University of Korea, Percutaneous Coronary Intervention Registry investigators. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011;97(23):1943–1950.
44.
SukhijaRAronowWSSureddiR. Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol. 2007;100(5):777–780.
45.
MatsumotoIMiyakeYMizukawaMTakagiY. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J. 2011;75(4):905–910.
46.
NishimuraMHashimotoTKobayashiH. Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol Dial Transplant. 2006;21(6):1640–1647.
47.
QuispeRManalacRJFaridiKF. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: the Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015;242(1):243–250.
48.
SarwarNSandhuMSRickettsSL; Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–1639.
49.
FrohlichJDobiasovaM. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003;49(11):1873–1880.
50.
DrexelHAczelSMarteT. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?Diabetes Care. 2005;28(5):108–114.
51.
GazianoJMHennekensCHO’DonnellCJBreslowJLBuringJE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96(8):2520–2525.
52.
JeppesenJHeinHOSuadicaniPGyntelbergF. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med. 2001;161(3):361–366.
53.
BarziFPatelAWoodwardM; Asia Pacific Cohort Studies Collaboration. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific Region. Ann Epidemiol. 2005;15(5):405–413.
